In a Houston laboratory at Rice University, researchers have engineered what amounts to a living factory small enough to fit on a patch of skin — one that continuously manufactures healing proteins exactly where wounds need them most. Elizabeth Kelley and her colleagues in Omid Veiseh's bioengineering lab have developed a cytokine factory patch designed to solve a stubborn problem in medicine: keeping the body's repair signals working long enough and strong enough to mend chronic wounds that conventional treatments struggle to heal.
The challenge is ancient but the solution is distinctly modern. Cytokines — the signaling proteins that orchestrate immune response and tissue regeneration — degrade rapidly and fail to accumulate at wound sites when delivered through traditional methods. Without sustained, localized delivery, the body's natural healing response fizzles out before the job is done. Veiseh's team addressed this by turning wound care into cellular manufacturing. The patch encapsulates ARPE-19 cells engineered to act as on-site factories, continuously secreting three key cytokines: IL-10, IL-12, and TGF-β. These cells live within a biocompatible matrix that lets nutrients and therapeutic proteins flow through while protecting the engineered cells from the host immune system's surveillance.
In preclinical studies published in Nature Biomedical Engineering, the patch demonstrated accelerated healing across both murine and porcine excisional wound models — rodents and pigs, the workhorses of translational medicine. Histology slides showed healed healthy skin in treated wounds versus the damaged tissue in untreated controls. More tellingly, RNA sequencing revealed that the patch activated key biological pathways involved in tissue regeneration and immune modulation, providing the molecular proof that something meaningful was happening beneath the surface.
"By maintaining a consistent presence of these signaling molecules at the wound site, we can more effectively engage the body's natural healing response," Veiseh explained. The data validated this claim: the continuous, localized delivery of cytokines supported the very biological processes the body ordinarily uses to repair itself, but amplified and sustained.
What makes this platform particularly powerful is its flexibility. The engineered cells can be adapted to produce different combinations of cytokines, growth factors, or other therapeutic proteins depending on the clinical need. Christian Schreib, assistant research professor in bioengineering and co-author of the study, sees future possibilities in real-time control. "The ability to tune both the type and timing of cytokine delivery opens the door to more precise control over the healing process," he said. Early concepts involve optogenetic control — using light to regulate cytokine secretion on demand.
The patch itself can vary in size and design, with indentations housing the cytokine-secreting cells. The system was developed with backing from the Rice Biotech Launch Pad, accelerating its path from laboratory concept toward clinical application. Beyond wound healing, Veiseh's team sees the cytokine factory framework as a broader platform for localized, cell-based delivery across diseases where sustained, site-specific signaling is critical. For now, chronic wounds — those that refuse to heal through conventional means — stand to benefit first. The living bandage represents a fundamental shift: instead of delivering one dose and hoping it sticks, the wound itself becomes a production facility, continuously manufacturing the exact healing signals it needs.